This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

John DaSilva
Scientist at Regeneron Pharmaceuticals


John DaSilva, Ph.D., is Associate Director of Oncology & Immune-Oncology at Regeneron Pharmaceuticals. Experienced researcher in the fields of cancer cell signaling, biologics, biparatopic antibodies, and antibody drug conjugate (ADC) development. Demonstrated success producing preclinical data supporting INDs and guiding several development programs. Leading discovery and development team from initial ADC design and screening to delivery of clinical development candidates for the treatment of cancer.

Agenda Sessions

  • A METxMET Bispecific Antibody and ADC for Cancer Therapy